Distalmotion
About
About Distalmotion
Distalmotion is a Swiss medical-device company that develops and manufactures the DEXTER Robotic Surgery System. Founded in 2012 as a spin-off from EPFL's Robotics Lab, the company designed DEXTER to integrate robotic assistance into established laparoscopic workflows. Surgeons operate from a sterile bedside console and can move between robotic and conventional techniques while retaining access to the patient and operating-room team.
DEXTER received CE marking in 2020 and began clinical use in 2021. US market authorization started with adult inguinal-hernia repair in 2024 and has expanded to additional general-surgery and gynecologic procedures; indications remain jurisdiction-specific. Distalmotion is headquartered in Lausanne and sells the system to hospitals and ambulatory surgery centres in the United States and Europe.
Products
Operations
Operating milestones
- Operating milestone
2025-11-18 - DEXTER had treated almost 3,000 patients across Europe and the United States by November 18, 2025. - DEXTER clinical patients treated across Europe and the United States
Source
Deployments
- Operating use
More than 4,000 patients treated with DEXTER - distalmotion-dexter
Source
Funding
- 2025-11-18 - Series G - $150M - Distalmotion closes $150M Series G for DEXTER expansion
The company completed private financing to develop and expand its robotics business. - source: globenewswire.com
Investors
- Revival Healthcare Capital - Lead - VC - 1 funding event - first seen 2025-11-18
Team
- Greg Roche - Chief Executive Officer - Leads commercial and organisational strategy for the DEXTER surgical-robotics business.
- Tony Collins - Chief Financial Officer - Leads finance for the surgical-robotics company.
- Sarah Moore - Chief Marketing Officer - Leads global marketing for the DEXTER surgical-robotics business.
- Sean McGrath - Chief People Officer - Leads people and organisational strategy.
- Lionel Flaction - Chief Technology Officer - Leads technology development for the DEXTER surgical-robotics platform.
Timeline
Events
- 2026-08-13 - Regulatory - FDA clears DEXTER for ventral hernia repair
The clearance expands DEXTER's U.S. label to the four highest-volume soft-tissue ambulatory procedure categories. Distalmotion reports that surgeons have used DEXTER in more than 4,000 patients. The system is designed for surgeon-controlled robotic assistance within established operating-room workflows.
Source - 2025-11-18 - Funding - Distalmotion closes $150M Series G for DEXTER expansion
The financing also included existing investors and supports clinical and product development. U.S. expansion focuses on ambulatory surgery centres and other outpatient care settings. DEXTER had treated almost 3,000 patients across Europe and the United States when the round was announced.
Source